Alfacalcidol is a synthetic analogue of vitamin D 3 that belongs to the bone-health therapeutic class. It is available as a generic medication and marketed under various brand names. In Hong Kong, alfacalcidol is supplied in capsule form (cap) with strengths of 0.25 µg and 0.5 µg. It is a prescription-only product and is regulated by the Hong Kong Department of Health.
Alfacalcidol (1-α-hydroxyvitamin D₃) is a prodrug that is rapidly converted in the liver to calcitriol, the active form of vitamin D. Calcitriol binds to vitamin D receptors in the intestine, kidney, and bone, enhancing calcium and phosphate absorption from the gut and promoting mineralisation of the skeletal matrix. The onset of action is typically within a few days, with peak biochemical effects occurring after 1-2 weeks of consistent therapy. Because the conversion step bypasses the renal 1-α-hydroxylase, alfacalcidol can be useful in patients with impaired kidney function.
These indications are recognised by regulatory agencies in Hong Kong and are supported by clinical guidelines for disorders of calcium metabolism.
Alfacalcidol has been investigated for several off-label purposes, including:
These applications are not approved by Hong Kong health authorities. Off-label use requires medical supervision and an individualized risk assessment.
This article provides educational information about alfacalcidol and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Alfacalcidol is a prodrug converted in the liver to calcitriol, the active hormone. This bypasses the kidney’s 1-α-hydroxylase step, making alfacalcidol useful in renal impairment.
Yes, but the combined effect on blood calcium can be significant. Coordinate dosing with your healthcare provider to avoid hypercalcaemia.
Serum calcium usually begins to rise within a few days, reaching a stable plateau after 1-2 weeks of consistent dosing.
Patients prone to nephrolithiasis should be monitored closely, as increased calcium absorption may raise stone risk. Discuss alternative strategies with your clinician.
Yes. Monitoring calcium, phosphate, and renal function every 2-4 weeks initially, then every 3-6 months, helps ensure safe therapy.
It is classified as a pregnancy-category C drug in many regions; use only if the potential benefits outweigh the risks and under specialist supervision.
Contact your prescriber for guidance; a temporary dose reduction may be recommended before restarting the usual regimen.
Capsules are typically white or off-white and may contain different inert fillers, but the active ingredient dose remains identical across reputable manufacturers.
Yes. Alfacalcidol raises active vitamin D (calcitriol) levels without necessarily increasing 25-hydroxyvitamin D, which is the standard screening test.
Sun exposure does not interfere with alfacalcidol’s action, but excessive sun without protection can still increase overall vitamin D load. Use sunscreen as recommended for skin health.
